“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mrs. Manju D Gupta
Chairman (Non Executive)
Mrs. Manju D. Gupta is one of the promoters of the Company. She has intimate knowledge of the Company right since inception. Mrs. Gupta has been a Member of the Board for over four decades and has been an important pillar of strength for the Company. She has wide business experience and expertise and has been on various Committees of the Board and also involved in the CSR activities of the Company. Mrs. Gupta has made significant contribution in building the Company as one of the top corporates in India.
Mrs. Manju D. Gupta was Executive Director of the Company till August 10, 2017. The Board of Directors elevated her as Non-Executive Chairperson of the Company effective August 11, 2017.
Dr. Kamal K Sharma
Vice Chairman (Non Executive)
Dr. Kamal K. Sharma is the Vice Chairman of the Board of Lupin Limited, in a Non-Executive capacity. In a career spanning more than four decades, Dr. Sharma has held a range of senior management positions managing projects, operations, corporate development and general management in the pharmaceuticals and chemicals industries. He was the Managing Director of Lupin Chemicals Limited which was rechristened Lupin Limited upon amalgamation with Lupin Laboratories Limited. Thereafter, he joined RPG Life Sciences, as President and Chief Executive Officer. In 2003 he rejoined Lupin Limited as Managing Director, following which he was appointed as Vice Chairman in 2013.
Dr. Sharma is a chemical engineer from Indian Institute of Technology (IIT), Kanpur, with a post-graduate diploma in industrial management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Ph.D. in economics from IIT, Mumbai. He has also completed an advanced management programme from Harvard Business School, Boston.
Ms. Vinita Gupta
Chief Executive Officer
Mr. Nilesh D Gupta
Mr. Ramesh Swaminathan
Executive Director, Global Chief Financial Officer & Head Corporate Affairs
Mr. Jean-Luc Belingard
Mr Belingard, a French national, graduated from Ecole des Hautes Etudes Commerciales (HEC), France and completed Master of Business Administration from Cornell University, USA. Mr Belingard started his career with Merck, Sharp and Dohme. He moved to F. Hoffman-La Roche, Basel, Switzerland. He was Member of the Executive Committee, F. Hoffman-La Roche Ltd. and Chief Executive Officer, Roche Diagnostics, Basel, Switzerland. He was Chief Executive Officer, bioMerieux-Pierre Fabre, France. He was Chairman and Chief Executive Officer, Ipsen Group, France. In 2011, he joined bioMerieux S.A. as Chief Executive Officer and became its Chairman in April 2014. Mr Belingard is a Member of the Board of Directors of Laboratory Corporation of America, (U.S.A.), Stallergenes (France/U.S.A.), Transgene (France) and Laboratoire Pierre Fabre, (France). He is also a Member of the Bill and Melinda Gates Foundation. Mr Belingard is also Foreign Trade Advisor to the French Government. Mr Belingard has been conferred upon the prestigious National Awards, Chevalier de I'Ordre National du Merite and Chevalier de la Legion d'Honneur awards.
Ms. Christine Mundkur
Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. She currently serves on the Board of Directors for MannKind Corporation in the U.S.
Ms. Mundkur holds a J.D. from the St. Louis University School of Law and also received a B.S. degree in chemistry from St. Louis University.
Mr. K B S Anand
Mr. Anand is a B. Tech (Mech. Engineering) from Indian Institute of Technology (IIT), Mumbai, (1977) and PGDM, Indian Institute of Management (IIM), Kolkata (1979).
Mr. Anand brings over four decades of experience with Asian Paints Limited, India’s leading paint company. He joined Asian Paints in 1979 and until 1989 he served in various capacities in the sales team. From 1989 to 1998 he served as the Factory Manager and managed the Paint manufacturing operations. From 1998 to 2008 he led the Sales and Marketing functions. From 2008 to 2012 he led the Decoratives business in India. In 2012, he was appointed as Managing Director & CEO. He retired from this role in March 2020.
Mr. Anand is well versed with managing board dynamics. He was nominated as the ‘Best CEO - Private Sector’ at the Forbes Leadership Awards in 2016 and was awarded the Qimpro Gold Standard in Business for Quality in 2017.
Mr. Anand is an Independent Director on the Board of Marico Ltd., Tata Chemicals Ltd. and Borosil Ltd. He is also Member of Nomination & Remuneration Committees of Marico Ltd. and Borosil Ltd.
Dr. Punita Kumar-Sinha
Punita Kumar-Sinha, PhD, CFA, has focused on investment management and financial markets during her 30-year career. She also has significant governance and Board experience across India and North America. Ms. Kumar-Sinha has been investing in emerging markets since the late 1980s and pioneered some of the first foreign investments in the Indian subcontinent in the early 1990s.
Currently, she is the Founder and Managing Partner, Pacific Paradigm Advisors, an independent investment advisory and management firm focused on Asia. She serves as an Independent Director for several companies in India including Infosys, JSW Steel, Blackstone Embassy REIT and SREI Infrastructure. Ms. Kumar-Sinha is also a Governor on the board of the CFA Institute, which is the premier association for investment professional globally.
Prior to this, Ms. Kumar-Sinha was a Senior Managing Director of Blackstone and the Head & Chief Investment Officer of Blackstone Asia Advisors. Ms. Kumar-Sinha was also the Senior Portfolio Manager and CIO for The India Fund (NYSE: IFN), one of the largest India funds in the US, for almost 15 years; during this time, she managed several Asia funds as well. Prior to joining Blackstone, Ms. Kumar-Sinha was a Managing Director and Senior Portfolio Manager at Oppenheimer Asset Management Inc. and CIBC World Markets, where she also managed India and Asia funds. She has also worked at Batterymarch (a Legg Mason company), Standish Ayer & Wood (a BNY Mellon company), JP Morgan, and IFC/World Bank.
Ms. Kumar-Sinha is frequently featured in the media and at global conferences as an expert commentator on Asian capital markets and women’s issues. She has also anchored many TV shows on major economic trends, key policy issues for India, and global capital markets. Ms. Kumar-Sinha has a PhD and a master’s in Finance from the Wharton School, University of Pennsylvania. She received her undergraduate degree in Chemical Engineering with Distinction from the Indian Institute of Technology, New Delhi. She has an MBA and is a CFA charter holder. Ms. Kumar-Sinha is a member of CFA Institute, a member of the Boston Security Analysts Society, a TiE Charter Member, and a member of the Council on Foreign Relations.
Ms. Kumar-Sinha has been awarded the Distinguished Alumni Award from IIT Delhi. In addition she was awarded the Best Woman Director 2016 by Asian Centre For Corporate Governance and Sustainability. Ms. Kumar-Sinha was featured as one of the top 2019 Directors to Watch: Racial and Ethnic Diversity by Directors and Boards publication.
Dr. Punita currently splits her time between Delhi and Boston, given she has commitments in both India and USA.
Mr. Robert Funsten
Mr. Robert Funsten is Counsel in the Corporate Practice Group of the law firm Brown Rudnick LLP in the USA. He has over twenty-five years of experience working with and advising life sciences companies in transactional, M&A and other matters. Prior to becoming Counsel at Brown Rudnick, Mr. Funsten was a partner at the law firm and Co-Chair of the law firm’s Global Life Sciences Group. Before joining Brown Rudnick, Mr. Funsten was a partner at various law firms and served as Senior Vice President, General Counsel and Corporate Secretary of Watson Pharmaceuticals, a publicly-held specialty pharmaceutical company, Vice President, General Counsel of Chiron Vision Corporation, an ophthalmic medical device company, and Corporate Secretary of ISTA Pharmaceuticals, a publicly-held pharmaceutical company. Mr. Funsten is currently consultant to and a Member of the Board of Directors of Exela Holdings, Inc., a privately held injectable pharmaceutical company.
Mr. Funsten received a J.D. from Stanford Law School and a B.A., magna cum laude from the University of California, Los Angeles.
Mr. Mark D. McDade
Mr. McDade is a Co-Founder and Partner at Qiming Venture Partners, USA where he built a strong investment team and made large number of high value investments in biotherapeutics, including cell and gene therapy and digital health.
He is a highly accomplished executive with excellent operating and leadership skills. During a biopharmaceutical career spanning over more than 37 years, he has held a progression of COO and CEO roles in complex businesses. He was most recently the number two executive at UCB Pharma, where he was exceptionally well-regarded and credited with providing steady and resilient leadership during a time of significant transformation. He has a breadth of experience with small and large molecules (biologic) products in a wide range of therapeutic areas. He has a strong track record of developing, launching, scaling and managing commercial products and has consistently delivered above-plan performance. He has extensive experience in all global regions and knows the complex, competitive dynamics in established and emerging markets around the world. His diverse experience with large, mid, small and development-stage companies is unique and provides him with an excellent strategic perspective, which serves him well in a board setting. He has considerable experience serving on the boards of public and private companies and has a very good understanding of governance.
He completed B.A. in History from Dartmouth College and MBA from Harvard Business School.
Committees of the Board of Directors.
Mr. Alok Sonig
CEO, US Generics
Head Global R&D & Biosimilars
Mr. Anil Kaushal
Dr. Cyrus Karkaria
Mr. Debabrata Chakravorty
Global Sourcing & Contract Manufacturing
Dr. Fabrice Egros
President – Growth Markets
Mr. Alan Butcher
Chief Corporate Development Officer
Mr. Naresh Gupta
President, API Plus & Global TB
Mr. Jon Stelzmiller
President, Specialty, USA
Mr. Rajeev Sibal
India Region Formulations (IRF)
Dr. Rajender Kamboj
President, Novel Drug Discovery and Development
Mr. Rajendra Chunodkar
President - Manufacturing Operations
Dr. Sofia Mumtaz
Pipeline Management and Legal
Mr. Sunil Makharia
Mr. Thierry Volle
Europe, Middle-East & Africa
Mr. Yashwant Mahadik
President, Global Human Resources
Mr. Johnny Mikell
President, Global Head of Quality
Mr. R V Satam
Ms. Shweta Munjal
Head - Corporate Communications